Retinoblastoma
Conditions
Brief summary
For the 3 studies: ocular preservation (absence of secondary enucleation) and absence of external beam radiotherapy at 18 months.
Detailed description
Evaluation or the risk of relapse by fundus examination under general anaesthesia until the age of 4 then without general anaesthesia., Prospective evaluation of the ocular and general side effects (short, medium and long term) of the intravenous chemotherapy, intra-arterial chemotherapy, combined to the local treatment as well as the intra-vitreal injections of melphalan., Evaluation of the response to intra-vitreal chemotherapy by melphalan., Study of the radiation doses received during intra-arterial procedures., Evaluate the number of patients presenting with another tumour.
Interventions
DRUGVINCRISTINE TEVA 1 mg/ml
DRUGsolution injectable
DRUGALKERAN 50 mg poudre et solvant pour solution pour perfusion Melphalan
DRUGsolution à diluer pour perfusion
DRUGsolution pour perfusion
DRUGMELPHALAN
Sponsors
Institut Curie
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For the 3 studies: ocular preservation (absence of secondary enucleation) and absence of external beam radiotherapy at 18 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation or the risk of relapse by fundus examination under general anaesthesia until the age of 4 then without general anaesthesia., Prospective evaluation of the ocular and general side effects (short, medium and long term) of the intravenous chemotherapy, intra-arterial chemotherapy, combined to the local treatment as well as the intra-vitreal injections of melphalan., Evaluation of the response to intra-vitreal chemotherapy by melphalan., Study of the radiation doses received during intra-arterial procedures., Evaluate the number of patients presenting with another tumour. | — |
Countries
France
Outcome results
None listed